Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients

Abstract

Epoetin beta, darbepoetin alfa, and epoetin beta pegol are effective and well-tolerated agents for managing anemia in Japanese pre-dialysis CKD patients. The intervals of ESA administration to maintain a patient's target hemoglobin were longer in the order of epoetin beta pegol> darbepoetin alfa > epoetin beta.

Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats

“…treatment for 9 weeks showed no influence on systolic blood pressure or heart rate in this study. Earlier reports have also indicated no elevation of blood pressure in CKD patients and rats (Aizawa et al, 2014;Kuwahara et al, 2013).…”

Relationship between anaemia management at haemodialysis initiation and patient prognosis

“…This was inferred as indicating significant efficacy of long‐acting ESA. In patients prior to haemodialysis, reports exist of the successful maintenance of Hb levels by switching from EPO . We divided Hb concentrations during haemodialysis into five groups to analyze prognosis (Fig.…”

Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents

“…We also checked the erythropoietin resistance index (ERI: dosage of epoetin / body weight / level of Hb). The dose of erythropoietin stimulating agents (ESA) was converted to that of epoetin using a dose conversion ratio (epoetin beta: epoetin beta pegol = 200: 0.93) . The serial process of levels of Hb and ERI were compared with each observation period and the usage of epoetin beta or epoetin beta pegol.…”